David Warshal

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

David S. Miller, Virginia L. Filiaci, Robert S. Mannel et al. · Journal of Clinical Oncology · 2020 · 340 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Prevalence and Predictors of Psychological Distress Among Women With Ovarian Cancer

Tina R. Norton, Sharon L. Manne, Stephen C. Rubin et al. · Journal of Clinical Oncology · 2004 · 178 citations · Full text

Medicine, Gynecology, Oncology +17